At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses the anti-CD38 monoclonal antibody, daratumumab, for the treatment of patients with pretreated multiple myeloma.
